<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320202</url>
  </required_header>
  <id_info>
    <org_study_id>RMTI-SFP-4</org_study_id>
    <nct_id>NCT01320202</nct_id>
  </id_info>
  <brief_title>Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients</brief_title>
  <acronym>CRUISE 1</acronym>
  <official_title>A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 1) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockwell Medical Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rockwell Medical Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the safety and efficacy of Soluble Ferric
      Pyrophosphate (SFP) dialysate solution in maintaining iron delivery for erythropoiesis in
      anemic adult patients with chronic kidney disease (CKD) receiving hemodialysis. Efficacy will
      be measured primarily by the change from baseline in hemoglobin (Hgb).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening: 2-3 weeks prior to enrollment in Stage 1.

      Stage 1 (Run-In): 1-4 weeks depending on qualification for Stage 2.

      Stage 2 (Randomized Blinded Treatment): 12 months unless withdrawn prematurely.

      Stage 3 (Open-Label Treatment): The duration of Stage 2 plus Stage 3 is intended to be 18
      months regardless of treatment assignment in Stage 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Hemoglobin at End-of-Treatment: Least-Squares Mean</measure>
    <time_frame>Hgb measured weekly; up to 48 weeks from the date of randomization</time_frame>
    <description>Mean change from baseline Hgb (the average of the three most recent Hgb values preceding randomization) assessments during the last one-sixth of the treatment period for patients who prematurely withdraw from study treatment, but will include a minimum of at least the last two Hgb values. Value is expressed as least-squares mean with standard error.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Hemoglobin at End-of-Treatment: Mean Baseline and End-of-Treatment Hgb</measure>
    <time_frame>Hgb measured weekly; up to 48 weeks from the date of randomization</time_frame>
    <description>Mean change from baseline Hgb (the average of the three most recent Hgb values preceding randomization) assessments during the last one-sixth of the treatment period for patients who prematurely withdraw from study treatment, but will include a minimum of at least the last two Hgb values. Values expressed are mean baseline and end-of-treatment Hgb, along with the mean difference (standard deviation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Serum Iron From Pre-dialysis to Post-dialysis.</measure>
    <time_frame>Up to 48 weeks from the date of randomization</time_frame>
    <description>The mean difference between the pre-dialysis and post-dialysis serum iron was calculated, using all post-baseline values obtained during Stage 2. Subjects could participate in Stage 2 for up to 48 weeks, provided that they did not complete Stage 2 early due to a protocol-mandated change in anemia management or withdraw from the study entirely for other reasons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in TSAT (Transferrin) From Pre-dialysis to Post-dialysis.</measure>
    <time_frame>Up to 48 weeks from the date of randomization</time_frame>
    <description>The mean difference between the pre-dialysis and post-dialysis TSAT (transferrin) was calculated, using all post-baseline values obtained during Stage 2. Subjects could participate in Stage 2 for up to 48 weeks, provided that they did not complete Stage 2 early due to a protocol-mandated change in anemia management or withdraw from the study entirely for other reasons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Unsaturated Iron Binding Capacity (UIBC) From Pre- to Post-dialysis.</measure>
    <time_frame>Up to 48 weeks from the date of randomization</time_frame>
    <description>The mean difference between the pre-dialysis and post-dialysis unsaturated iron binding capacity (UIBC) was calculated, using all post-baseline values obtained during Stage 2. Subjects could participate in Stage 2 for up to 48 weeks, provided that they did not complete Stage 2 early due to a protocol-mandated change in anemia management or withdraw from the study entirely for other reasons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell or Whole Blood Transfusion: Number of Patients Receiving Transfusion</measure>
    <time_frame>up to 48 weeks from the date of randomization</time_frame>
    <description>The number of patients requiring red blood cell or whole blood transfusion while in the randomized treatment stage (Stage 2). Patients remained in Stage 2 until they met protocol-defined criteria for Stage 2 completion or until they had participated in Stage 2 for 48 weeks (whichever came sooner). If a patient was transfused, they were withdrawn from Stage 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell or Whole Blood Transfusion: Number of Units Transfused</measure>
    <time_frame>up to 48 weeks from the date of randomization</time_frame>
    <description>The total number of units of red blood cells or whole blood that were received by patients while in the randomized treatment stage (Stage 2). This number is the total number of units received across all randomized patients in each treatment group (it is not the average number of units received per patient). Patients remained in Stage 2 until they met protocol-defined criteria for Stage 2 completion or until they had participated in Stage 2 for 48 weeks (whichever came sooner). If a patient was transfused, they were withdrawn from Stage 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Change From Baseline to End-of-Treatment (EoT) for: Reticulocyte Hemoglobin Content (CHr), Ferritin, and Pre-Dialysis Serum Iron Panel</measure>
    <time_frame>Up to 48 weeks from the date of randomization</time_frame>
    <description>A comparison of the lab values at the end-of-treatment (EoT) to baseline was performed, and the percentage of change from baseline was calculated for the following lab parameters: reticulocyte hemoglobin content (CHr), Ferritin, pre-dialysis unbound iron-binding capacity (UIBC), pre-dialysis serum iron, pre-dialysis transferrin, pre-dialysis total iron-binding capacity TIBC), and transferrin saturation (TSAT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End-of-Treatment (EoT) in Pre-Dialysis Unsaturated Iron-Binding Capacity (UIBC), Serum Iron, and Total Iron-Binding Capacity (TIBC)</measure>
    <time_frame>Up to 48 weeks from the date of randomization</time_frame>
    <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Pre-Dialysis Unsaturated Iron-Binding Capacity (UIBC), Pre-Dialysis Serum Iron, and Pre-Dialysis Total Iron-Binding Capacity (TIBC) will be quantified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End-of-Treatment (EoT) in Reticulocyte Hemoglobin Content (CHr)</measure>
    <time_frame>Up to 48 weeks from the date of randomization</time_frame>
    <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Reticulocyte Hemoglobin Content (CHr) will be quantified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End-of-Treatment (EoT) in Ferritin</measure>
    <time_frame>Up to 48 weeks from the date of randomization</time_frame>
    <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Ferritin will be quantified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin</measure>
    <time_frame>Up to 48 weeks from the date of randomization</time_frame>
    <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin will be quantified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin Saturation (TSAT)</measure>
    <time_frame>Up to 48 weeks from the date of randomization</time_frame>
    <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin Saturation (TSAT) will be quantified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of Hemoglobin Concentration: Temporal Trend</measure>
    <time_frame>Hgb measured weekly; up to 48 weeks from the date of randomization</time_frame>
    <description>The mean temporal trend of hemoglobin concentration value changes, as measured weekly from baseline until the end of participation in Stage 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of Hemoglobin Concentration: Residual Standard Deviation</measure>
    <time_frame>Hgb measured weekly; up to 48 weeks from the date of randomization</time_frame>
    <description>The mean residual standard deviation of hemoglobin concentration value changes, as measured weekly from baseline until the end of participation in Stage 2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">305</enrollment>
  <condition>Renal Failure Chronic Requiring Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Soluble Ferric Pyrophosphate (SFP) in dialysate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dialysate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Soluble Ferric Pyrophosphate (SFP)</intervention_name>
    <description>Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.</description>
    <arm_group_label>Soluble Ferric Pyrophosphate (SFP) in dialysate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard dialysate</intervention_name>
    <description>Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.</description>
    <arm_group_label>Standard Dialysate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Stage 1:

        Main Inclusion Criteria:

          -  Adult subject ≥ 18 years of age undergoing chronic hemodialysis three or four times
             per week for chronic kidney disease (CKD) for at least 4 months, and expected to
             remain on hemodialysis three to four times weekly and be able to complete the duration
             of the study.

          -  Received IV iron therapy between 6 months and 2 weeks prior to enrollment in order to
             replace iron losses resulting from hemodialysis procedure.

          -  Mean Screening Hgb ≥ 9.5 to ≤ 11.5 grams per deciliter (g/dL).

          -  Mean Screening Transferrin Saturation (TSAT) ≥ 15% to ≤ 40%.

          -  Mean Screening serum ferritin ≥ 200 to ≤ 800 micrograms per liter (µg/L).

          -  If being administered epoetin, darbepoetin, or CERA, epoetin dose ≤ 45,000 Units
             (U)/week, darbepoetin dose ≤ 200 micrograms (µg)/week, or CERA dose ≤ 400 micrograms
             (µg)/month during the four weeks prior to enrollment.

        Main Exclusion Criteria:

          -  Patient has living kidney donor identified or living-donor kidney transplant
             scheduled. (Note: Patients awaiting deceased-donor transplant need not be excluded.)

          -  Vascular access for dialysis with femoral catheter or non-tunneled catheter.

          -  Received a total of &gt; 800 milligrams (mg) IV iron during the 8 weeks prior to
             enrollment

          -  If being administered an ESA, route of administration change or ESA dose change &gt; 35%
             (i.e., [max - min dose]/max dose &gt; 0.35) over the 2 weeks prior to screening.

          -  Serum albumin &lt; 3.0 grams per deciliter (g/dL) any time over the 8 weeks prior to
             enrollment.

          -  Red Blood Cell (RBC) or whole blood transfusion within 12 weeks prior to enrollment.

        Stage 2:

        Main Inclusion Criteria:

          -  Patient currently enrolled in the Stage 1 run-in period of study.

          -  Undergoing chronic hemodialysis three or four times per week for chronic kidney
             disease (CKD), and expected to remain on hemodialysis three to four times weekly and
             be able to complete duration of the study.

          -  Mean Hgb ≥ 9.5 to ≤ 11.5 g/dL over the three most recent consecutive every-week
             measurements prior to randomization.

          -  Stable Hgb defined as ≤ 1.0 g/dL difference between the maximum and minimum Hgb values
             over the 3 weeks immediately prior to randomization.

          -  Mean TSAT ≥ 15% to ≤ 40% over the two most recent consecutive every-other-week
             measurements prior to randomization.

          -  Mean serum ferritin ≥ 200 to ≤ 800 µg/L over the two most recent consecutive
             every-other-week measurements prior to randomization.

          -  If being administered epoetin, darbepoetin, or CERA, epoetin dose ≤ 45,000 U/week,
             darbepoetin dose ≤ 200 µg/week, or CERA dose ≤ 400 µg/month during the four weeks
             prior to randomization.

        Main Exclusion Criteria:

          -  Patient has living kidney donor identified or living-donor kidney transplant
             scheduled. (Note: Patients awaiting deceased-donor transplant need not be excluded.)

          -  Vascular access for dialysis with femoral catheter or non-tunneled catheter.

          -  Received any amount of IV iron during the 4 weeks prior to randomization.

          -  If being administered an (Erythropoietin Stimulating Agent) ESA, change in dose over
             the 6 weeks immediately prior to randomization.

          -  Serum albumin &lt; 3.0 g/dL any time over the 8 weeks prior to randomization.

          -  RBC or whole blood transfusion during Stage 1.

        Stage 3:

        Main Inclusion Criteria:

          -  Patient randomized in Stage 2 who has completed the full duration of Stage 2 and less
             than 4 weeks have elapsed since completion of Stage 2, OR

          -  Patient in Stage 2 who has been prematurely withdrawn from Stage 2 for
             protocol-defined Protocol-Mandated Change in Anemia Management and less than 4 weeks
             have elapsed since withdrawal from Stage 2, OR

          -  Patient in Stage 2 who has been prematurely withdrawn from Stage 2 for Hgb &gt;11.5 g/dL
             over ≥ 1 week confirmed by ≥ 2 consecutive measurements AND an associated increase in
             Hgb by ≥ 1 g/dL over 4 weeks.

        Main Exclusion Criteria:

          -  Patient in Stage 2 who has been prematurely withdrawn from Stage 2 for any reason
             other than as noted in inclusion criteria above.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ray Pratt, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rockwell Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cudahy</city>
        <state>California</state>
        <zip>90201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <zip>91764</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <zip>93065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <zip>91792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yuba City</city>
        <state>California</state>
        <zip>95991</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Ridgewood</city>
        <state>New York</state>
        <zip>11385</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosedale</city>
        <state>New York</state>
        <zip>11422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yonkers</city>
        <state>New York</state>
        <zip>10704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <zip>29150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shorewood</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caguas</city>
        <zip>00725</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carolina</city>
        <zip>00987</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <results_first_submitted>March 20, 2015</results_first_submitted>
  <results_first_submitted_qc>April 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2015</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>SFP</keyword>
  <keyword>Hemodialysis-dependent chronic renal failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
          <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Standard Dialysate</title>
          <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Comp 48 Wks in St 2</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Comp St 2 Due to ESA/IV Iron Needs</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled in St 3</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed St 3</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-protocol change to ESA or IV iron</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>kidney transplant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>blood transfusion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>moved/changed dialysis</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>sponsor request</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ineligible</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>regained renal function</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat population: all randomized subjects, regardless of whether they received any investigational product.</population>
      <group_list>
        <group group_id="B1">
          <title>Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
          <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.</description>
        </group>
        <group group_id="B2">
          <title>Standard Dialysate</title>
          <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 18 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="152"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="305"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" spread="12.56"/>
                    <measurement group_id="B2" value="59.9" spread="13.01"/>
                    <measurement group_id="B3" value="58.3" spread="12.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>post-dialysis body weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.08" spread="23.264"/>
                    <measurement group_id="B2" value="83.15" spread="22.166"/>
                    <measurement group_id="B3" value="83.61" spread="22.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.48" spread="10.197"/>
                    <measurement group_id="B2" value="169.17" spread="9.350"/>
                    <measurement group_id="B3" value="168.82" spread="9.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Hemoglobin at End-of-Treatment: Least-Squares Mean</title>
        <description>Mean change from baseline Hgb (the average of the three most recent Hgb values preceding randomization) assessments during the last one-sixth of the treatment period for patients who prematurely withdraw from study treatment, but will include a minimum of at least the last two Hgb values. Value is expressed as least-squares mean with standard error.</description>
        <time_frame>Hgb measured weekly; up to 48 weeks from the date of randomization</time_frame>
        <population>modified intent-to-treat populations: all randomized subjects who received at least one dose of study medication and had at least one post-dose hemoglobin measurement obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Hemoglobin at End-of-Treatment: Least-Squares Mean</title>
          <description>Mean change from baseline Hgb (the average of the three most recent Hgb values preceding randomization) assessments during the last one-sixth of the treatment period for patients who prematurely withdraw from study treatment, but will include a minimum of at least the last two Hgb values. Value is expressed as least-squares mean with standard error.</description>
          <population>modified intent-to-treat populations: all randomized subjects who received at least one dose of study medication and had at least one post-dose hemoglobin measurement obtained.</population>
          <units>grams per liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.15"/>
                    <measurement group_id="O2" value="-3.0" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>LS Mean (SE) and p-value are from ANCOVA model with baseline Hgb as covariate. Model also includes indicator variable for baseline ESA dose stratum.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means between SFP &amp; PBO</param_type>
            <param_value>3.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.40</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Serum Iron From Pre-dialysis to Post-dialysis.</title>
        <description>The mean difference between the pre-dialysis and post-dialysis serum iron was calculated, using all post-baseline values obtained during Stage 2. Subjects could participate in Stage 2 for up to 48 weeks, provided that they did not complete Stage 2 early due to a protocol-mandated change in anemia management or withdraw from the study entirely for other reasons.</description>
        <time_frame>Up to 48 weeks from the date of randomization</time_frame>
        <population>modified intent-to-treat population: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Serum Iron From Pre-dialysis to Post-dialysis.</title>
          <description>The mean difference between the pre-dialysis and post-dialysis serum iron was calculated, using all post-baseline values obtained during Stage 2. Subjects could participate in Stage 2 for up to 48 weeks, provided that they did not complete Stage 2 early due to a protocol-mandated change in anemia management or withdraw from the study entirely for other reasons.</description>
          <population>modified intent-to-treat population: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
          <units>micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mean pre-dialysis serum iron</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="4.15"/>
                    <measurement group_id="O2" value="10.8" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mean post-dialysis serum iron</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="8.64"/>
                    <measurement group_id="O2" value="11.5" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serum iron change from pre- to post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="8.70"/>
                    <measurement group_id="O2" value="0.6" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in TSAT (Transferrin) From Pre-dialysis to Post-dialysis.</title>
        <description>The mean difference between the pre-dialysis and post-dialysis TSAT (transferrin) was calculated, using all post-baseline values obtained during Stage 2. Subjects could participate in Stage 2 for up to 48 weeks, provided that they did not complete Stage 2 early due to a protocol-mandated change in anemia management or withdraw from the study entirely for other reasons.</description>
        <time_frame>Up to 48 weeks from the date of randomization</time_frame>
        <population>modified intent-to treat: all randomized subjects who had at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in TSAT (Transferrin) From Pre-dialysis to Post-dialysis.</title>
          <description>The mean difference between the pre-dialysis and post-dialysis TSAT (transferrin) was calculated, using all post-baseline values obtained during Stage 2. Subjects could participate in Stage 2 for up to 48 weeks, provided that they did not complete Stage 2 early due to a protocol-mandated change in anemia management or withdraw from the study entirely for other reasons.</description>
          <population>modified intent-to treat: all randomized subjects who had at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mean pre-dialysis TSAT(transferrin)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" spread="6.86"/>
                    <measurement group_id="O2" value="22.4" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mean post-dialysis TSAT(transferrin)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" spread="15.94"/>
                    <measurement group_id="O2" value="22.2" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre- to post-dialysis change in TSAT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" spread="15.83"/>
                    <measurement group_id="O2" value="-0.4" spread="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Unsaturated Iron Binding Capacity (UIBC) From Pre- to Post-dialysis.</title>
        <description>The mean difference between the pre-dialysis and post-dialysis unsaturated iron binding capacity (UIBC) was calculated, using all post-baseline values obtained during Stage 2. Subjects could participate in Stage 2 for up to 48 weeks, provided that they did not complete Stage 2 early due to a protocol-mandated change in anemia management or withdraw from the study entirely for other reasons.</description>
        <time_frame>Up to 48 weeks from the date of randomization</time_frame>
        <population>modified intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Unsaturated Iron Binding Capacity (UIBC) From Pre- to Post-dialysis.</title>
          <description>The mean difference between the pre-dialysis and post-dialysis unsaturated iron binding capacity (UIBC) was calculated, using all post-baseline values obtained during Stage 2. Subjects could participate in Stage 2 for up to 48 weeks, provided that they did not complete Stage 2 early due to a protocol-mandated change in anemia management or withdraw from the study entirely for other reasons.</description>
          <population>modified intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
          <units>micromole per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mean pre-dialysis UIBC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.49" spread="6.797"/>
                    <measurement group_id="O2" value="32.27" spread="6.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mean post-dialysis UIBC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.48" spread="7.911"/>
                    <measurement group_id="O2" value="34.51" spread="7.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre- to post-dialysis change in UIBC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.86" spread="6.604"/>
                    <measurement group_id="O2" value="2.38" spread="3.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Red Blood Cell or Whole Blood Transfusion: Number of Patients Receiving Transfusion</title>
        <description>The number of patients requiring red blood cell or whole blood transfusion while in the randomized treatment stage (Stage 2). Patients remained in Stage 2 until they met protocol-defined criteria for Stage 2 completion or until they had participated in Stage 2 for 48 weeks (whichever came sooner). If a patient was transfused, they were withdrawn from Stage 2.</description>
        <time_frame>up to 48 weeks from the date of randomization</time_frame>
        <population>Intent-to-Treat (ITT): all patients randomized are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cell or Whole Blood Transfusion: Number of Patients Receiving Transfusion</title>
          <description>The number of patients requiring red blood cell or whole blood transfusion while in the randomized treatment stage (Stage 2). Patients remained in Stage 2 until they met protocol-defined criteria for Stage 2 completion or until they had participated in Stage 2 for 48 weeks (whichever came sooner). If a patient was transfused, they were withdrawn from Stage 2.</description>
          <population>Intent-to-Treat (ITT): all patients randomized are included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Red Blood Cell or Whole Blood Transfusion: Number of Units Transfused</title>
        <description>The total number of units of red blood cells or whole blood that were received by patients while in the randomized treatment stage (Stage 2). This number is the total number of units received across all randomized patients in each treatment group (it is not the average number of units received per patient). Patients remained in Stage 2 until they met protocol-defined criteria for Stage 2 completion or until they had participated in Stage 2 for 48 weeks (whichever came sooner). If a patient was transfused, they were withdrawn from Stage 2.</description>
        <time_frame>up to 48 weeks from the date of randomization</time_frame>
        <population>Intent-to-Treat (ITT): all patients randomized are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cell or Whole Blood Transfusion: Number of Units Transfused</title>
          <description>The total number of units of red blood cells or whole blood that were received by patients while in the randomized treatment stage (Stage 2). This number is the total number of units received across all randomized patients in each treatment group (it is not the average number of units received per patient). Patients remained in Stage 2 until they met protocol-defined criteria for Stage 2 completion or until they had participated in Stage 2 for 48 weeks (whichever came sooner). If a patient was transfused, they were withdrawn from Stage 2.</description>
          <population>Intent-to-Treat (ITT): all patients randomized are included.</population>
          <units>units of red blood cells or whole blood</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Change From Baseline to End-of-Treatment (EoT) for: Reticulocyte Hemoglobin Content (CHr), Ferritin, and Pre-Dialysis Serum Iron Panel</title>
        <description>A comparison of the lab values at the end-of-treatment (EoT) to baseline was performed, and the percentage of change from baseline was calculated for the following lab parameters: reticulocyte hemoglobin content (CHr), Ferritin, pre-dialysis unbound iron-binding capacity (UIBC), pre-dialysis serum iron, pre-dialysis transferrin, pre-dialysis total iron-binding capacity TIBC), and transferrin saturation (TSAT).</description>
        <time_frame>Up to 48 weeks from the date of randomization</time_frame>
        <population>modified intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Change From Baseline to End-of-Treatment (EoT) for: Reticulocyte Hemoglobin Content (CHr), Ferritin, and Pre-Dialysis Serum Iron Panel</title>
          <description>A comparison of the lab values at the end-of-treatment (EoT) to baseline was performed, and the percentage of change from baseline was calculated for the following lab parameters: reticulocyte hemoglobin content (CHr), Ferritin, pre-dialysis unbound iron-binding capacity (UIBC), pre-dialysis serum iron, pre-dialysis transferrin, pre-dialysis total iron-binding capacity TIBC), and transferrin saturation (TSAT).</description>
          <population>modified intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CHr: % of change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="3.800"/>
                    <measurement group_id="O2" value="-2.73" spread="4.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ferritin: % of change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" spread="27.68"/>
                    <measurement group_id="O2" value="-28.5" spread="34.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dialysis UIBC: % of change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.36" spread="53.186"/>
                    <measurement group_id="O2" value="7.62" spread="14.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dialysis serum iron: % of change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.644" spread="53.1728"/>
                    <measurement group_id="O2" value="-4.628" spread="29.0307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dialysis transferrin: % change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.718" spread="8.5133"/>
                    <measurement group_id="O2" value="2.633" spread="9.7691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dialysis TIBC: % of change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="9.255"/>
                    <measurement group_id="O2" value="2.88" spread="10.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dialysis TSAT: % of change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="44.99"/>
                    <measurement group_id="O2" value="-7.8" spread="26.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End-of-Treatment (EoT) in Pre-Dialysis Unsaturated Iron-Binding Capacity (UIBC), Serum Iron, and Total Iron-Binding Capacity (TIBC)</title>
        <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Pre-Dialysis Unsaturated Iron-Binding Capacity (UIBC), Pre-Dialysis Serum Iron, and Pre-Dialysis Total Iron-Binding Capacity (TIBC) will be quantified.</description>
        <time_frame>Up to 48 weeks from the date of randomization</time_frame>
        <population>modified Intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End-of-Treatment (EoT) in Pre-Dialysis Unsaturated Iron-Binding Capacity (UIBC), Serum Iron, and Total Iron-Binding Capacity (TIBC)</title>
          <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Pre-Dialysis Unsaturated Iron-Binding Capacity (UIBC), Pre-Dialysis Serum Iron, and Pre-Dialysis Total Iron-Binding Capacity (TIBC) will be quantified.</description>
          <population>modified Intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
          <units>micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline UIBC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.91" spread="6.784"/>
                    <measurement group_id="O2" value="30.77" spread="6.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT UIBC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.76" spread="13.734"/>
                    <measurement group_id="O2" value="33.03" spread="7.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UIBC: Change from Baseline to EoT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="13.265"/>
                    <measurement group_id="O2" value="2.14" spread="4.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Serum Iron</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.976" spread="3.9192"/>
                    <measurement group_id="O2" value="11.443" spread="3.9198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT Serum Iron</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.911" spread="4.5412"/>
                    <measurement group_id="O2" value="10.389" spread="3.4941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Iron: Change from Baseline to EoT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.196" spread="4.7462"/>
                    <measurement group_id="O2" value="-1.051" spread="3.6562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline TIBC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.88" spread="7.458"/>
                    <measurement group_id="O2" value="42.22" spread="7.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT TIBC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.59" spread="8.140"/>
                    <measurement group_id="O2" value="43.40" spread="7.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIBC: Change from Baseline to EoT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="4.051"/>
                    <measurement group_id="O2" value="1.08" spread="4.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End-of-Treatment (EoT) in Reticulocyte Hemoglobin Content (CHr)</title>
        <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Reticulocyte Hemoglobin Content (CHr) will be quantified.</description>
        <time_frame>Up to 48 weeks from the date of randomization</time_frame>
        <population>modified Intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End-of-Treatment (EoT) in Reticulocyte Hemoglobin Content (CHr)</title>
          <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Reticulocyte Hemoglobin Content (CHr) will be quantified.</description>
          <population>modified Intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
          <units>picograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline CHr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.37" spread="1.985"/>
                    <measurement group_id="O2" value="32.57" spread="1.953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT CHr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.12" spread="2.016"/>
                    <measurement group_id="O2" value="31.64" spread="2.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHr: Change from Baseline to EoT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="1.203"/>
                    <measurement group_id="O2" value="-0.91" spread="1.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End-of-Treatment (EoT) in Ferritin</title>
        <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Ferritin will be quantified.</description>
        <time_frame>Up to 48 weeks from the date of randomization</time_frame>
        <population>modified Intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End-of-Treatment (EoT) in Ferritin</title>
          <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Ferritin will be quantified.</description>
          <population>modified Intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
          <units>micrograms per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Ferritin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509.6" spread="194.16"/>
                    <measurement group_id="O2" value="511.3" spread="209.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT Ferritin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="440.7" spread="216.41"/>
                    <measurement group_id="O2" value="366.9" spread="224.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ferritin: Change from Baseline to EoT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-72.3" spread="133.40"/>
                    <measurement group_id="O2" value="-143.1" spread="188.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin</title>
        <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin will be quantified.</description>
        <time_frame>Up to 48 weeks from the date of randomization</time_frame>
        <population>modified Intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin</title>
          <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin will be quantified.</description>
          <population>modified Intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
          <units>grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Pre-Dialysis Transferrin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.928" spread="0.3427"/>
                    <measurement group_id="O2" value="1.908" spread="0.3475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT Pre-Dialysis Transferrin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.958" spread="0.3767"/>
                    <measurement group_id="O2" value="1.957" spread="0.3731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Dialysis Ferritin: Change from Baseline to EoT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029" spread="0.1695"/>
                    <measurement group_id="O2" value="0.044" spread="0.1883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin Saturation (TSAT)</title>
        <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin Saturation (TSAT) will be quantified.</description>
        <time_frame>Up to 48 weeks from the date of randomization</time_frame>
        <population>modified Intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin Saturation (TSAT)</title>
          <description>The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin Saturation (TSAT) will be quantified.</description>
          <population>modified Intent-to-treat: all randomized subjects who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
          <units>percentage of saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Pre-Dialysis TSAT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="8.13"/>
                    <measurement group_id="O2" value="27.1" spread="7.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT Pre-Dialysis TSAT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="8.52"/>
                    <measurement group_id="O2" value="24.0" spread="7.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Dialysis TSAT: Change from Baseline to EoT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="9.16"/>
                    <measurement group_id="O2" value="-3.0" spread="7.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variability of Hemoglobin Concentration: Temporal Trend</title>
        <description>The mean temporal trend of hemoglobin concentration value changes, as measured weekly from baseline until the end of participation in Stage 2.</description>
        <time_frame>Hgb measured weekly; up to 48 weeks from the date of randomization</time_frame>
        <population>modified intent to treat: all randomized subjects who received at least one dose of study medication and had at least one post-dose hemoglobin measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Variability of Hemoglobin Concentration: Temporal Trend</title>
          <description>The mean temporal trend of hemoglobin concentration value changes, as measured weekly from baseline until the end of participation in Stage 2.</description>
          <population>modified intent to treat: all randomized subjects who received at least one dose of study medication and had at least one post-dose hemoglobin measured.</population>
          <units>grams per liter per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.060" spread="0.298"/>
                    <measurement group_id="O2" value="0.002" spread="0.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variability of Hemoglobin Concentration: Residual Standard Deviation</title>
        <description>The mean residual standard deviation of hemoglobin concentration value changes, as measured weekly from baseline until the end of participation in Stage 2.</description>
        <time_frame>Hgb measured weekly; up to 48 weeks from the date of randomization</time_frame>
        <population>modified intent to treat: all randomized subjects who received at least one dose of study medication and had at least one post-dose hemoglobin measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Variability of Hemoglobin Concentration: Residual Standard Deviation</title>
          <description>The mean residual standard deviation of hemoglobin concentration value changes, as measured weekly from baseline until the end of participation in Stage 2.</description>
          <population>modified intent to treat: all randomized subjects who received at least one dose of study medication and had at least one post-dose hemoglobin measured.</population>
          <units>grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.104" spread="2.220"/>
                    <measurement group_id="O2" value="4.588" spread="1.949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Hemoglobin at End-of-Treatment: Mean Baseline and End-of-Treatment Hgb</title>
        <description>Mean change from baseline Hgb (the average of the three most recent Hgb values preceding randomization) assessments during the last one-sixth of the treatment period for patients who prematurely withdraw from study treatment, but will include a minimum of at least the last two Hgb values. Values expressed are mean baseline and end-of-treatment Hgb, along with the mean difference (standard deviation).</description>
        <time_frame>Hgb measured weekly; up to 48 weeks from the date of randomization</time_frame>
        <population>modified intent-to-treat: all randomized patients who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
            <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 Placebo (Standard Dialysate)</title>
            <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week for up to 48 weeks in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Hemoglobin at End-of-Treatment: Mean Baseline and End-of-Treatment Hgb</title>
          <description>Mean change from baseline Hgb (the average of the three most recent Hgb values preceding randomization) assessments during the last one-sixth of the treatment period for patients who prematurely withdraw from study treatment, but will include a minimum of at least the last two Hgb values. Values expressed are mean baseline and end-of-treatment Hgb, along with the mean difference (standard deviation).</description>
          <population>modified intent-to-treat: all randomized patients who received at least one dose of study drug and had at least one post-dose hemoglobin measured.</population>
          <units>grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mean baseline hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.6" spread="5.91"/>
                    <measurement group_id="O2" value="109.0" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mean end-of-treatment hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.1" spread="12.53"/>
                    <measurement group_id="O2" value="105.2" spread="13.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mean change in Hemoglobin at end-of-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="11.67"/>
                    <measurement group_id="O2" value="-3.9" spread="12.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>In Stage 2, subjects were randomized to placebo or SFP. They were in Stage 2 for up to 48 weeks. Upon completion of Stage 2, subjects could enter the open-label Stage 3 (all received SFP). The maximum total time on study (Stage 2 + Stage 3) was 72 weeks.</time_frame>
      <desc>The number of subjects included in the safety population = 300, which is 5 patients fewer than the number of patients randomized. This discrepancy is due to the fact that the Safety population includes only those subjects exposed to study drug. Five subjects withdrew from Stage 2 and 2 subjects withdrew from Stage 3 prior to exposure.</desc>
      <group_list>
        <group group_id="E1">
          <title>Stage 2 Placebo (Standard Dialysate)</title>
          <description>0 micrograms (µg) of iron / deciliter (dL) of dialysate.
Standard dialysate: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week in Stage 2 for up to 48 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Stage 2 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
          <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week in Stage 2 for up to 48 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Stage 3 Soluble Ferric Pyrophosphate (SFP) in Dialysate</title>
          <description>11 micrograms (µg) of iron / deciliter (dL) of dialysate.
Soluble Ferric Pyrophosphate (SFP): Upon completion of Stage 2, patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week in Stage 3 for up to 72 weeks of total study participation (Stage 2 + Stage 3).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ANAEMIA OF CHRONIC DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK FIRST DEGREE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERPARATHYROIDISM SECONDARY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PORTAL HYPERTENSIVE GASTROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>STENT-GRAFT ENDOLEAK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ARTERIOVENOUS GRAFT SITE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>INFECTED SKIN ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="10" subjects_affected="5" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>RENAL CYST INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA POSTOPERATIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA ANEURYSM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA SITE COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>COMMINUTED FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>MUSCLE RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>MUSCLE STRAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CERVICAL SPINAL STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CHONDROCALCINOSIS PYROPHOSPHATE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>POLYMYALGIA RHEUMATICA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>SPONDYLOLISTHESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>CERVIX CARCINOMA STAGE 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>COLORECTAL CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HAEMANGIOMA OF LIVER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>OVARIAN LOW MALIGNANT POTENTIAL TUMOUR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HEPATIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL CYST HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ENDOMETRIAL HYPERPLASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CARDIOVERSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ACCELERATED HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE EMERGENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="148" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="151"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="149"/>
                <counts group_id="E3" events="45" subjects_affected="30" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="25" subjects_affected="14" subjects_at_risk="151"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="149"/>
                <counts group_id="E3" events="31" subjects_affected="20" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="151"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="149"/>
                <counts group_id="E3" events="27" subjects_affected="14" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" events="15" subjects_affected="6" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA SITE COMPLICATION</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="151"/>
                <counts group_id="E2" events="30" subjects_affected="17" subjects_at_risk="149"/>
                <counts group_id="E3" events="58" subjects_affected="25" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="14" subjects_affected="7" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA THROMBOSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HAEMODIALYSIS-INDUCED SYMPTOM</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E3" events="199" subjects_affected="39" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PROCEDURAL DIZZINESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPOTENSION</sub_title>
                <counts group_id="E1" events="216" subjects_affected="41" subjects_at_risk="151"/>
                <counts group_id="E2" events="174" subjects_affected="43" subjects_at_risk="149"/>
                <counts group_id="E3" events="494" subjects_affected="68" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="25" subjects_affected="13" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E3" events="15" subjects_affected="8" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>VITAMIN D DEFICIENCY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="34" subjects_affected="9" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="20" subjects_affected="11" subjects_at_risk="151"/>
                <counts group_id="E2" events="15" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E3" events="33" subjects_affected="10" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="149"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="151"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="149"/>
                <counts group_id="E3" events="52" subjects_affected="26" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="151"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="149"/>
                <counts group_id="E3" events="53" subjects_affected="38" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="151"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="149"/>
                <counts group_id="E3" events="27" subjects_affected="21" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E3" events="34" subjects_affected="22" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, Clinical Research &amp; Operations</name_or_title>
      <organization>Rockwell Medical</organization>
      <phone>248-960-9009</phone>
      <email>rd@rockwellmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

